We recorded higher incidences of treatment-related grade @ diarrhoea with afatinib ( @ -LSB- @ % -RSB- vs nine -LSB- @ % -RSB- ) , of grade @ stomatitis with afatinib ( @ -LSB- @ % -RSB- vs none ) , and of grade @ rash or acne with erlotinib ( @ -LSB- @ % -RSB- vs @ -LSB- @ % -RSB- ) .